



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 3		<b>Complete if Known</b>	
		Application Number	09/997,974
		Filing Date	November 30, 2001
		First Named Inventor	Daniela Salvemini
		Group Art Unit	1623
		Examiner Name	Kathleen Kohler Fonda
		Attorney Docket Number	60019610-0235

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
LCM	59	US-3,903,297	09-02-1975	Robert	

Examiner Signature		Date Considered	4-14-04
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449B/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/997,974	
			Filing Date	November 30, 2001	
			First Named Inventor	Daniela Salvemini	
			Group Art Unit	1623	
			Examiner Name	Kathleen Kohler Fonda	
Sheet	2	of	3	Attorney Docket No.	60019610-0235
<b>OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
LCM	60	MARZULLO et al., "Opiate Receptor Function May Be Modulated Through an Oxidation-Reduction Mechanism," Science, 1980, pp. 1171-1173, Vol. 208.			
LCM	61	CADET, "Free Radical Mechanisms in the Central Nervous System: An Overview," Int. J. Neurosci., 1988, pp. 13-18, Vol. 40.			
LCM	62	MARSHALL, "Solid Oral Dosage Forms," Chapter 10 of Modern Pharmaceutics, 1979, pp. 359-427, Vol. 7.			
LCM	63	HARGREAVES et al., "Basic Section - A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," Pain, 1988, pp. 77-88, Vol. 32.			
LCM	64	TALLARIDA et al., "Statistical Analysis of Drug-Drug and Site-Site Interactions with Osobolograms," Life Sciences, 1987, pp. 947-961, Vol. 45.			
LCM	65	OSSIPOV et al., "An Isobolographic Analysis of the Antinociceptive Effect of Systemically and Intrathecally Administered Combinations of Clonidine and Opiates," J. Pharmacol. Exp. Ther., 1990, pp. 1107-1116, Vol. 255.			
LCM	66	PORRECA et al., "Short Communication - Modulation of Morphine Antinociception by Peripheral [Leu <sup>5</sup> ]enkephalin: A Synergistic Interaction," Euro. J. Pharm., 1990, pp. 463-468, Vol. 179.			
LCM	67	HUNSKAAR et al., "The Formalin Test in Mice: Dissociation Between Inflammatory and Non-Inflammatory Pain," Pain, 1987, pp. 103-114, Vol. 30.			
LCM	68	OSSIPOV et al., "Characterization of Supraspinal Antinociceptive Actions of Opioid Delta Agonists in the Rat," Pain, 1995, pp. 287-293, Vol. 62.			
LCM	69	OSSIPOV et al., "The Increase in Morphine Antinociceptive Potency Produced by Carrageenan-Induced Hindpaw Inflammation is Blocked by Naltrindole, a Selective $\delta$ -Opioid Antagonist," Neurosci. Lett., 1995, p. 173-176, Vol. 184.			
LCM	70	OSSIPOV et al., "Inhibition by Spinal Morphine of the Tail-Flick Response is Attenuated in Rats with Nerve Ligation Injury," Neurosci. Lett., 1995, pp. 83-86, Vol. 199.			
LCM	71	OSSIPOV et al., "The Loss of Antinociceptive Efficacy of Spinal Morphine in Rats with Nerve Ligation Injury is Prevented by Reducing Spinal Afferent Drive," Neurosci. Lett., 1995, pp. 87-90, Vol. 199.			


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Lugh  4-14-04



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/997,974		
		Filing Date	November 30, 2001		
		First Named Inventor	Daniela Salvemini		
		Group Art Unit	1623		
Examiner Name	Kathleen Kohler Fonda				
Sheet	3	of	3	Attorney Docket No.	60019610-0235
<b>OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
LCM	72	KOCHER et al., "Basic Section - The Effect of Carrageenan-Induced Inflammation on the Sensitivity of Unmyelinated Skin Nociceptors in the Rat," Pain, 1987, pp. 363-373, Vol. 29.			
LCM	73	KOCHER, "A Proposal for a Generally Application <i>de minimis</i> Dose," Health Physics, 1987, pp. 117-121, Vol. 53.			
LCM	74	KOCHER et al., "Analysis of $\alpha$ -Smooth-Muscle Actin mRNA Expression in Rat Aortic Smooth-Muscle Cells Using Specific cDNA Probe," Differentiation, 1987, pp. 201-209, Vol. 34.			
LCM	75	KOCHER et al., "Electron Dose-Rate Conversion Factors for External Exposure of the Skin From Uniformly Deposited Activity on the Body Surface," Health Physics, 1987, pp. 135-141, Vol. 53.			
LCM	76	KOCHER, "Evaluation of a Terrestrial Food-Chain Model Using Natural Analogs," Health Physics, 1987, pp. 79-82, Vol. 52.			
Examiner Signature				Date Considered	4-14-04

23135501V-1